Company Pharmacyte Biotech Inc OTC Bulletin Board

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sector Other Pharmaceuticals

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

18/03	PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
2023	PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	CI

PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.

Managers	Title	Age	Since
Joshua Silverman CEO	Chief Executive Officer	53	15/22/15
Carlos Trujillo DFI	Director of Finance/CFO	66	01/15/01
José Iglesias CTO	Chief Tech/Sci/R&D Officer	-	10/20/10
Lilli Brandtner PRN	Corporate Officer/Principal	-	10/15/10

Members of the board	Title	Age	Since
Robert Weinstein BRD	Director/Board Member	64	14/22/14
Joshua Silverman CEO	Chief Executive Officer	53	15/22/15
Wayne Walker BRD	Director/Board Member	65	28/22/28
Carlos Trujillo DFI	Director of Finance/CFO	66	01/15/01
Jonathan Schechter BRD	Director/Board Member	50	15/22/15
Michael Abecassis BRD	Director/Board Member	65	10/17/10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	21,604,315	7,767,289 ( 35.95 %)	13,150,919 ( 60.87 %)	35.95 %
Stock B	0	35,000	0	0

Name	Equities	%	Valuation
Intracoastal Capital LLC 5.622 %	475,884	5.622 %	1 M $
The K2 Principal Fund LP 3.869 %	327,503	3.869 %	694 306 $
Daniel C. Allen 3.072 %	260,000	3.072 %	551 200 $
Geode Capital Management LLC 2.366 %	200,281	2.366 %	424 596 $
Vanguard Group, Inc. (Subfiler) 2.063 %	174,602	2.063 %	370 156 $
Ayrton Capital LLC 1.088 %	92,087	1.088 %	195 224 $
Equitec Proprietary Markets LLC 0.9773 %	82,727	0.9773 %	175 381 $
Jonathan Schechter 0.5907 %	50,000	0.5907 %	106 000 $
Joshua Silverman 0.5907 %	50,000	0.5907 %	106 000 $
Renaissance Technologies LLC 0.5174 %	43,800	0.5174 %	92 856 $

Name	Equities	%	Valuation
FEMASYS INC. -.--%	0	-.--%	0 $

PharmaCyte Biotech, Inc.

3960 Howard Hughes Parkway Suite 500

89169, Las Vegas

http://pharmacyte.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.11%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.59%	371B
MERCK & CO., INC.	+19.97%	331B
ABBVIE INC.	+7.09%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals